Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?

被引：6

作者：

Jiang W. ^{[1
]}

Krishnan R.R. ^{[1
]}

机构：

[1] Dept. of Psychiatry/Behav. Sciences, Duke University Medical Center, Durham, NC 27710

来源：

Current Psychiatry Reports | 2004年 / 6卷 / 3期

关键词：

Fluoxetine; Ischemic Heart Disease; Paroxetine; Unstable Angina; Sertraline;

D O I：

10.1007/s11920-004-0065-1

中图分类号：

学科分类号：

摘要：

Recent studies have uncovered more and more evidence demonstrating the adverse relationship between depression and ischemic heart disease. One of the most significant mechanisms that may explain the adverse relationship is the increased platelet activity, otherwise known as aggregation, observed to occur in patients with depression or ischemic heart disease. Platelet activity is further elevated in patients with depression and ischemic heart disease. Selective serotonin reuptake inhibitors are antidepressants and also act like platelet inhibitors. The results of large-scale clinical trials suggest that the use of selective serotonin reuptake inhibitors may reduce cardiac events in post-myocardial infarction patients or in those with unstable angina that may be related to the effects of selective serotonin reuptake inhibitors on platelet aggregation. Copyright © 2004 by Current Science Inc.

引用

页码：202 / 209

页数：7

共 50 条

[41] Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery [J].

Mead, Gillian E. ;

Hsieh, Cheng-Fang ;

Lee, Rebecca ;

Kutlubaev, Mansur A. ;

Claxton, Anne ;

Hankey, Graeme J. ;

Hackett, Maree L. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11)

[42] Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients [J].

Eap, CB ;

Baumann, P .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01) :51-63

[43] Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors [J].

Samuel, Nephy G. ;

Seifert, Charles F. .

ANNALS OF PHARMACOTHERAPY, 2017, 51 (03) :226-231

[44] Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? [J].

Illi, Ari ;

Poutanen, Outi ;

Setala-Soikkeli, Eija ;

Kampman, Olli ;

Viikki, Merja ;

Huhtala, Heini ;

Mononen, Nina ;

Haraldsson, Susann ;

Koivisto, Pasi A. ;

Leinonen, Esa ;

Lehtimaki, Terho .

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2011, 261 (02) :95-102

[45] Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard [J].

Van Ameringen M. ;

Mancini C. ;

Oakman J.M. ;

Farvolden P. .

CNS Drugs, 1999, 11 (4) :307-315

[46] Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors epidemiology, mechanisms and management [J].

Jiménez-Jiménez F.J. ;

Molina J.A. .

CNS Drugs, 2000, 14 (5) :367-379

[47] Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity [J].

Tiradentes, R. V. ;

Pires, J. G. P. ;

Silva, N. F. ;

Ramage, A. G. ;

Santuzzi, C. H. ;

Futuro Neto, H. A. .

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2014, 47 (07) :554-559

[48] Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions [J].

Mandrioli, R. ;

Mercolini, L. ;

Saracino, M. A. ;

Raggi, M. A. .

CURRENT MEDICINAL CHEMISTRY, 2012, 19 (12) :1846-1863

[49] Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia: Analysis of the French Pharmacovigilance Database [J].

Oger, F. ;

Buire, A. C. ;

Trenque, T. .

DRUG SAFETY, 2008, 31 (10) :932-932

[50] Selective serotonin reuptake inhibitors for migraine prophylaxis [J].

Landy, S ;

McGinnis, J ;

Curlin, D ;

Laizure, SC .

HEADACHE, 1999, 39 (01) :28-32

← 1 2 3 4 5 →